While more insight is expected to come from the ongoing randomized evaluation of beta blocker and angiotensin-converting enzyme-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT) trial, the current treatment strategy for MINOCA relies on the results from observational studies which suggest better outcomes with the use of antiplatelet drugs, statins, renin-angiotensin system blockers, and beta blockers [23]. The gene discussed is ACE; the disease is myocardial infarction.